“Review on Development and Validation of RP-HPLC Method, And Techniques for Vorasidenib in Bulk Drug and Pharmaceutical Dosage Forms”

Vorasidenib, a novel dual inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2), has gained considerable attention for its therapeutic potential in the treatment of low-grade gliomas and other IDH-mutant malignancies. Accurate and reliable analytical methods are essential for the quantitative estimation of Vorasidenib in bulk drug and pharmaceutical dosage forms to ensure quality, safety, and efficacy. Among the available analytical techniques, Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) has emerged as the method of choice due to its sensitivity, selectivity, reproducibility, and cost-effectiveness. This review highlights the development and validation strategies of RP-HPLC methods for Vorasidenib, focusing on critical parameters such as selection of stationary and mobile phases, optimization of chromatographic conditions, and detection wavelength. Method validation is discussed in accordance with ICH guidelines, covering accuracy, precision, linearity, specificity, robustness, limit of detection (LOD), and limit of quantitation (LOQ). Furthermore, the review emphasizes the application of validated methods in routine quality control and stability studies of pharmaceutical formulations. Overall, the article provides comprehensive insights into RP-HPLC method development for Vorasidenib, serving as a valuable reference for researchers and pharmaceutical analysts engaged in drug analysis and regulatory submissions.

Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) Vorasidenib,limit of detection (LOD)

1. Drug information, https://patient.info/in/medicine/aceclofenac-tablets-for-pain-andinflammation-preservex [Google Scholar] [Crossref]

2. Brogden, M., Wiseman, L. R., Pub. Med., 52(1), 113 - 124, (1996). https://www.ncbi.nlm.nih.gov/pubmed/8799688 [Google Scholar] [Crossref]

3. British national formulary (BNF 41) British medical association, London, 464, (2001). [Google Scholar] [Crossref]

4. European pharmacopoeia, 4 th edition, Council of Europe, Strasbourg Cedex, France, 1281, (2002). [Google Scholar] [Crossref]

5. British pharmacopoeia, Volume-1, Her majesty’s stationary office, London, 35 – 37, (2002). [Google Scholar] [Crossref]

6. https://www.researchgate.net/publication/259206360_Validated_StabilityIndicating_Assay_Method_for_Simultaneous_Determination_of_Aceclofenac_and_ Thiocolchicoside_using_RP-HPLC [Google Scholar] [Crossref]

7. Thiocolchicoside+ Aceclofenac pharmacology, Medicine India, https://www.medicineindia.org/pharmacology-for-generic/3225/thiocolchicosideaceclofenac [Google Scholar] [Crossref]

8. Sengar, M. R., Gandhi, S. V., Patil, U. P., and Rajmane, V. S., Asian J. Pharm. Clin. Res., 3(2), 89-91, (2010). https://www.ajpcr.com/Vol3Issue2/248.pdf [Google Scholar] [Crossref]

9. http://en.wikipedia.org/wiki/thiocolchicoside, Assessedon date 24 April (2017). [Google Scholar] [Crossref]

10. Paramasivam Balan and Nagappan kannappan., Int. Cur. Pharma. J., 3(7), 296-300, (2014). DOI: http://dx.DOI.org/10.3329/icpj.v3i7.19078 [Google Scholar] [Crossref]

11. O’Neil, M. J., The Merck index - An encyclopedia of chemicals, drugs and biologicals, Maryadele, J. O’Neil. Eds., 14th edition, Merck research lab, Division of Merck and co. Inc., Whitehouse station, N J, 1603, (2006). [Google Scholar] [Crossref]

12. Indian Pharmacopoeia, Volume-2, Govt. of India, New Delhi, Ministry of Health and Family Welfare, 681-683, (2007). [Google Scholar] [Crossref]

13. Vishnu P Choudhari., Anuruddha R Chabukswar., Mangesh U Tryambake., and Sachin N Savakhande., Int. J. Pharm. Sci. Rev. Res., 7( 2), 32, (2011). [Google Scholar] [Crossref]

14. Carta, M., Murru, L., Botta, P., Talani, G., Sechi,G., de riu, P., Sanna, E., and Biggio, G., Neuropharm. 51(4), 805-815, (2006). DOI: 10.1016/j.neuropharm.2006.05.023 [Google Scholar] [Crossref]

15. Venkata Subba Reddy, S., and Rajeshwar Dutt, K., Int. J. of Pharmacy and Analytical Research, 3(1), 55-66, (2014) [Google Scholar] [Crossref]

16. Samanthula, G., Shrigod, V. V., and Patel, P. N., Pub. Mid Journals., 64(8), 429- 435, (2013) [Google Scholar] [Crossref]

17. Vishnu P Choudhari., Rahul P Raut., Madhusmita Sahoo., Pratima K Syal., Santosh, N., Asawaree A Hable., and Bhanudas S Kuchekar., J. Pharm. Res., 4(6), 1820- 1823, (2012). [Google Scholar] [Crossref]

18. Madhusmita Sahoo., Pratima Syal., Asawaree A Hable., Rahul P Raut., Vishnu P Choudhari., and Bhanudas S Kuchekar., Pharm. Methods., 2(3), 178-183, (2011). DOI: 10.4103/2229-4708.90358 [Google Scholar] [Crossref]

19. Rajan Rele, V., J. Chem. and Pharm. Research, 7(7), 1007-1012, (2015). [Google Scholar] [Crossref]

20. Validation of analytical procedure, Text and methodology Q2 (R1), International conference on harmonization of technical requirements for registration of pharmaceuticals for human use, ICH harmonized tripartite guideline, (2005). [Google Scholar] [Crossref]

21. USP, (30th ed), United States Pharmacopeia, Rockville, United States Pharmacopeial Convention, (2007). [Google Scholar] [Crossref]

22. Calvin, J., and Kellerroy, A., Editors Giddings, Advances in chromatography published by Edward Arnold, Volume-4, (1967). https://www.abebooks.com/booksearch/title/advanceschromatography /author/giddings-keller [Google Scholar] [Crossref]

23. Text on validation of analytical procedures, International conference on harmonization, (1993). [Google Scholar] [Crossref]

24. http://www.laboratoryequipment.com/article/2012/12/analytical-instruments-drivepharmaceutical-r-d [Google Scholar] [Crossref]

25. Tswett, M. S., Proc. Warsaw Natural Biol. Soc., 14, 20, (1903). [Google Scholar] [Crossref]

26. Tswett, M. S., Chromophils in Animal and Plant World, Doctor of Science dissertation, Warsaw, 379, (1910). [Google Scholar] [Crossref]

27. Palmer, L. S., Carotenoids and Related Pigments, The Chromophlipids, ACS Monograph Series, American Chemical Society, New York, 316, (1922) [Google Scholar] [Crossref]

28. http://shodhganga.inflibnet.ac.in/bitstream/10603/110204/8/08_part%20a%20section %201.pd [Google Scholar] [Crossref]

29. https://www.fda.gov/downloads/Drugs/Guidances/UCM134409.pdf [Google Scholar] [Crossref]

• Development and Evaluation of Floating Alginate Beads of Esomeprazole
• Determination of pKa Value for Ranolazine and Atenolol Using UV Spectroscopy
• The Science of Sustained-Release Medications
• Development of Proteomics in Clinical Medicine
• Advances on Quinoline Derivatives: A Review of Synthesis and Biological Activities